Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Notes Payables (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Notes Payables for 10 consecutive years, with $149.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Notes Payables changed N/A year-over-year to $149.8 million, compared with a TTM value of $149.8 million through Jun 2025, changed N/A, and an annual FY2020 reading of $7.1 million, up 25.41% over the prior year.
  • Notes Payables was $149.8 million for Q2 2025 at Heron Therapeutics, up from $7.6 million in the prior quarter.
  • Across five years, Notes Payables topped out at $149.8 million in Q2 2025 and bottomed at $7.6 million in Q1 2021.